Aclaris Therapeutics Announces Issuance of New US Patent for Topical Solutions

Aclaris Therapeutics, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,675,639 covering the formulation and methods of use of A-101 40% topical solution (A-101 40%), an investigational drug being developed for the treatment of seborrheic keratosis (SK), and A-101 45% topical solution (A-101 45%), an investigational drug being developed for the treatment of common warts. This patent contains 70 claims and expires in July 2035.

The patent is part of an intellectual property portfolio that includes other issued patents and numerous patent applications in the US and major international markets covering high concentration topical hydrogen peroxide formulations, methods of use, and applicators for the treatment of certain dermatological conditions, including SK, common warts, molluscum contagiosum, skin tags (acrochordons), and other dermatological conditions.

“This patent is an important component of Aclaris’ expanding intellectual property portfolio covering both A-101 40% and 45% topical solutions, along with other high concentration formulations and their methods of treating dermatological diseases,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

A-101 40% Topical Solution, an investigational drug, is a proprietary, high-concentration hydrogen peroxide formulation for the treatment of SK. It is being developed as a non-invasive, in-office treatment administered by physicians or other licensed health care professionals. In clinical trials, patients treated with A-101 40% achieved statistically and clinically significant improvement in clearing SK lesions compared to placebo and with a similar adverse event profile. A-101 40% is designed to work by penetrating into the SK lesion and causing oxidative damage, which can ultimately result in the sloughing of the SK cells. A-101 40% has been the focus of a robust clinical development program in which over 700 patients have been treated with A-101. A-101 45% is also in clinical development for the treatment of common warts (verruca vulgaris).

Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist. For more information, visit www.aclaristx.com.